EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 496 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR For Children with Neuroblastoma, Trial Results Highlight Continued Evolution of Treatment September 23, 2019 Can Eating Soy Cause Breast Cancer? October 19, 2021 Real-World Patients with Cancer Show Lower Survival Times and Treatment-Associated Survival... March 18, 2025 Let’s Talk About Bubbles July 16, 2020 Load more HOT NEWS EMA Recommends Extension of Indications for Venetoclax Celebrating 10 years of partnership with NIVEA Sun ΠΟΝΟΣ Breast Cancer Patient Who Continued Teaching Throughout Her Treatment Wins Teacher...
